FLT3 and acute myeloid leukemia: The RATIFY study randomized over 700 young patients (range 18–59 years) with untreated AML and FLT3-ITD (77%) or FLT3-TKD (23%) mutation to receive midostaurin or placebo with induction chemotherapy.